Your browser doesn't support javascript.
loading
Benzodiazepine use in Sao Paulo, Brazil
Campanha, Angela Maria; Ravagnani, Beatriz; Milhorança, Igor André; Bernik, Márcio Antonini; Viana, Maria Carmen; Wang, Yuan-Pang; Andrade, Laura Helena.
  • Campanha, Angela Maria; Universidade de Sao Paulo. Faculdade de Medicina FMUSP. Nucleo de Epidemiologia Psiquiatrica (LIM-23). Sao Paulo. BR
  • Ravagnani, Beatriz; Universidade de Sao Paulo. Faculdade de Medicina FMUSP. Nucleo de Epidemiologia Psiquiatrica (LIM-23). Sao Paulo. BR
  • Milhorança, Igor André; Universidade de Sao Paulo. Faculdade de Medicina FMUSP. Nucleo de Epidemiologia Psiquiatrica (LIM-23). Sao Paulo. BR
  • Bernik, Márcio Antonini; Universidade de Sao Paulo. Faculdade de Medicina FMUSP. Programa de Ansiedade. Sao Paulo. BR
  • Viana, Maria Carmen; Universidade Federal do Espirito Santo. Centro de Estudos e Pesquisa em Epidemiologia Psiquiatrica (CEPEP). Departamento de Medicina Social. Vitoria. BR
  • Wang, Yuan-Pang; Universidade de Sao Paulo. Departamento e Instituto de Psiquiatria, Faculdade de Medicina FMUSP. Nucleo de Epidemiologia Psiquiatrica (LIM-23). Sao Paulo. BR
  • Andrade, Laura Helena; Universidade de Sao Paulo. Faculdade de Medicina FMUSP. Nucleo de Epidemiologia Psiquiatrica (LIM-23). Sao Paulo. BR
Clinics ; 75: e1610, 2020. tab
Article in English | LILACS | ID: biblio-1133432
ABSTRACT

OBJECTIVES:

To report the prevalence and factors associated with the use of benzodiazepines in the general population and those with a mental health condition in the metropolitan area of São Paulo, Brazil.

METHODS:

5,037 individuals from the Sao Paulo Megacity Mental Health Survey data were interviewed using the Composite International Diagnostic Interview, designed to generate DSM-IV diagnoses. Additionally, participants were asked if they had taken any medication in the previous 12 months for the treatment of any mental health condition.

RESULTS:

The prevalence of benzodiazepine use ranged from 3.6% in the general population to 7.8% among subjects with a mental health condition. Benzodiazepine use was more prevalent in subjects that had been diagnosed with a mood disorder as opposed to an anxiety disorder (14.7% vs. 8.1%, respectively). Subjects that had been diagnosed with a panic disorder (33.7%) or bipolar I/II (23.3%) reported the highest use. Individuals aged ≥50 years (11.1%), those with two or more disorders (11.2%), those with moderate or severe disorders (10%), and those that used psychiatric services (29.8%) also reported higher use.

CONCLUSION:

These findings give an overview of the use of benzodiazepines in the general population, which will be useful in the public health domain. Benzodiazepine use was higher in those with a mental health condition, with people that had a mood disorder being the most vulnerable. Furthermore, females and the elderly had high benzodiazepine use, so careful management in these groups is required.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Benzodiazepines / Mental Disorders Type of study: Diagnostic study / Prevalence study / Risk factors Limits: Female / Humans / Male Country/Region as subject: South America / Brazil Language: English Journal: Clinics Journal subject: Medicine Year: 2020 Type: Article Affiliation country: Brazil Institution/Affiliation country: Universidade Federal do Espirito Santo/BR / Universidade de Sao Paulo/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Benzodiazepines / Mental Disorders Type of study: Diagnostic study / Prevalence study / Risk factors Limits: Female / Humans / Male Country/Region as subject: South America / Brazil Language: English Journal: Clinics Journal subject: Medicine Year: 2020 Type: Article Affiliation country: Brazil Institution/Affiliation country: Universidade Federal do Espirito Santo/BR / Universidade de Sao Paulo/BR